EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen

Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway

(2015) Adrian von Witzleben et al.   CANCER RESEARCH

YAP in MAPK pathway targeted therapy resistance

(2015) Keith T Flaherty et al.   CELL CYCLE

The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer

(2015) S. Song et al.   CLINICAL CANCER RESEARCH

Molecular targeted therapies in advanced or metastatic chordoma patients: Facts and hypotheses

(2015) Loïc Lebellec et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression

(2015) Chunbo He et al.   EMBO Molecular Medicine

Imatinib in advanced chordoma: A retrospective case series analysis

(2015) Nadia Hindi et al.   EUROPEAN JOURNAL OF CANCER

Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

(2015) Assuntina G. Sacco et al.   JOURNAL OF CLINICAL ONCOLOGY

Building a global consensus approach to chordoma: a position paper from the medical and patient community

(2015) Silvia Stacchiotti et al.   LANCET ONCOLOGY

Comprehensive characterization of the Published Kinase Inhibitor Set

(2015) Jonathan M Elkins et al.   NATURE BIOTECHNOLOGY

Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

(2015) C. R. Heery et al.   Cancer Immunology Research

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

(2015) Emily Padfield et al.   Frontiers in Oncology

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine

(2015) Duane H. Hamilton et al.   Oncotarget

Durable stabilization of three chordoma cases by bevacizumab and erlotinib

(2014) T. Asklund et al.   ACTA ONCOLOGICA

The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis

(2014) Christina Therkildsen et al.   ACTA ONCOLOGICA

Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies

(2014) Yook-Hwan Noh et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Seeding Collaborations to Advance Kinase Science with the GSK Published Kinase Inhibitor Set (PKIS)

(2014) David Drewry et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Emerging therapies for adult soft tissue sarcoma

(2014) Stefano Radaelli et al.   Expert Review of Anticancer Therapy

Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer

(2014) Takayasu Kurata et al.   INVESTIGATIONAL NEW DRUGS

Afatinib in NSCLC harbouring EGFR mutations

(2014) Filippo de Marinis et al.   LANCET ONCOLOGY

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Phenotypic screening in cancer drug discovery — past, present and future

(2014) John G. Moffat et al.   NATURE REVIEWS DRUG DISCOVERY

Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1

(2014) Edwin Choy et al.   PLoS One

Phase II study on lapatinib in advanced EGFR-positive chordoma†

(2013) S. Stacchiotti et al.   ANNALS OF ONCOLOGY

EGFR signaling and autophagy dependence for growth, survival, and therapy resistance

(2013) Barry Jutten et al.   CELL CYCLE

Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines

(2013) D C Swinney   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: A new treatment for metastatic soft tissue sarcoma

(2013) Girolamo Ranieri et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Phenotypic screens as a renewed approach for drug discovery

(2013) Wei Zheng et al.   DRUG DISCOVERY TODAY

The Hippo pathway: regulators and regulations

(2013) F.-X. Yu et al.   GENES & DEVELOPMENT

Promising biomarkers for predicting the outcomes of patients withKRASwild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: A systematic review with meta-analysis

(2013) Zu-Yao Yang et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors

(2013) S. Tjulandin et al.   INVESTIGATIONAL NEW DRUGS

Epidermal Growth Factor Receptor Targeting in Head and Neck Cancer: Have We Been Just Skimming the Surface?

(2013) Aaron R. Hansen et al.   JOURNAL OF CLINICAL ONCOLOGY

Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma

(2013) Jason M. Davies et al.   JOURNAL OF NEUROSURGERY

The quest to overcome resistance to EGFR-targeted therapies in cancer

(2013) Curtis R Chong et al.   NATURE MEDICINE

The ErbB/HER family of protein-tyrosine kinases and cancer

(2013) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Erlotinib Inhibits Growth of a Patient-Derived Chordoma Xenograft

(2013) I-Mei Siu et al.   PLoS One

Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis

(2013) Shen Keren et al.   TUMOR BIOLOGY

The Role of Epidermal Growth Factor Receptor in Cancer Metastasis and Microenvironment

(2013) Takamitsu Sasaki et al.   Biomed Research International

Phase II Study of Imatinib in Advanced Chordoma

(2012) Silvia Stacchiotti et al.   JOURNAL OF CLINICAL ONCOLOGY

An integrated functional genomics approach identifies the regulatory network directed by brachyury (T ) in chordoma

(2012) Andrew C Nelson et al.   JOURNAL OF PATHOLOGY

Chordoma: current concepts, management, and future directions

(2012) Brian P Walcott et al.   LANCET ONCOLOGY

Cancer Vaccines Targeting the Epithelial-Mesenchymal Transition: Tissue Distribution of Brachyury and Other Drivers of the Mesenchymal-Like Phenotype of Carcinomas

(2012) Duane H. Hamilton et al.   SEMINARS IN ONCOLOGY

Aldo–Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers

(2012) Toshiyuki Matsunaga et al.   Frontiers in Pharmacology

Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup

(2011) John C. Stellwagen et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review

(2011) Simon G Launay et al.   BMC CANCER

PET response and tumor stabilization under erlotinib and bevacizumab treatment of an intracranial lesion non-invasively diagnosed as likely chordoma

(2011) T. Asklund et al.   CLINICAL NEUROPATHOLOGY

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype

(2011) Birgit Hotz et al.   Gastric Cancer

Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target

(2011) Wesley Hsu et al.   JOURNAL OF NEUROSURGERY

Recurrent Chromosomal Copy Number Alterations in Sporadic Chordomas

(2011) Long Phi Le et al.   PLoS One

An overview of the c-MET signaling pathway

(2011) Shawna Leslie Organ et al.   Therapeutic Advances in Medical Oncology

AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer

(2010) D. M. Hickinson et al.   CLINICAL CANCER RESEARCH

Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study

(2010) Nadège Presneau et al.   JOURNAL OF PATHOLOGY

The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target

(2010) Asem Shalaby et al.   JOURNAL OF PATHOLOGY

Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas

(2010) E. Tamborini et al.   NEURO-ONCOLOGY

Brachyury Expression in Extra-axial Skeletal and Soft Tissue Chordomas: A Marker that Distinguishes Chordoma From Mixed Tumor/Myoepithelioma/Parachordoma in Soft Tissue

(2009) Roberto Tirabosco et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Response to erlotinib in a patient with treatment refractory chordoma

(2009) Nimit Singhal et al.   ANTI-CANCER DRUGS

Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors

(2009) Mark A. Seefeld et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors

(2009) F. Gellibert et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway

(2009) N Presneau et al.   BRITISH JOURNAL OF CANCER

Aberrant Hyperactivation of Akt and Mammalian Target of Rapamycin Complex 1 Signaling in Sporadic Chordomas

(2009) S. Han et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

(2009) Tetsuya Mitsudomi et al.   FEBS Journal

Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas

(2009) Asem AE Shalaby et al.   MODERN PATHOLOGY

Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib

(2008) Ola Lindèn et al.   ACTA ONCOLOGICA

The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

(2008) Adrian J. Folkes et al.   JOURNAL OF MEDICINAL CHEMISTRY